NMT cP12

Drug Profile

NMT cP12

Alternative Names: NMT-cP12

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeoMatrix Therapeutics
  • Class Peptides; Skin disorder therapies
  • Mechanism of Action Platelet-derived growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Burns

Most Recent Events

  • 31 Oct 2017 NMT cP12 receives Fast Track designation for Burns in USA before October 2017
  • 31 Oct 2017 NMT cP12 receives Orphan Drug status for Burns in USA before October 2017
  • 31 Oct 2017 NeoMatrix plans a phase I trial for Burns (Healthy volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top